Keyword: Gilead Sciences

Gilead Sciences balked at licensing the U.S. government's HIV-prevention patent rights, and now the feds are striking back.

Amid Gilead Sciences' flagging sales, HIV med Biktarvy has been a rare shining light. New safety data over a competitor could help its case.

AbbVie’s Skyrizi joins pharma TV spending sibling drug Humira in October list of top outlays.

In a long-running hep C patent dispute, Merck failed to convince an appeals court to revive a multibillion-dollar infringement verdict against Gilead.

Without transparency, it's hard to evaluate whether the spending amounts to smart public policy or a boondoggle that primarily benefits drugmakers.

If Gilead’s investors are worried the company’s new leadership team won’t pony up to support key launches, they don’t need to be, its CEO says.

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

While investors don't fancy megamergers, smaller deals in oncology could be the winning ticket, analysts have found.

For the second month in a row, AbbVie’s Humira, Gilead Sciences' Truvada and Allergan’s Botox topped pharma TV spending in that order.